Evidence map›Paper›PMID 42433530›Full record

ArticleQuantitative imaging in medicine and surgery2026

Impact of field number and monitor units per segment on magnetic resonance-guided hypofractionated stereotactic radiotherapy for brain metastases: plan quality, deliverability, and robustness trade-offs.

Shan Ren, Jinrong He, Sheng Han, Nuo Xu, Wenyang Wang, Shipai Zhu, An Li, Shoupeng Liu, Jialu Lai, Xiaodong Peng and 1 more

Abstract read
In one paragraph

Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shan Ren *Department of Oncology, West China School of Medicine, Sichuan University, Sichuan University Affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, Chengdu, China.
Jinrong He *Radiotherapy Physics & Technology Center, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Sheng HanDepartment of Oncology, West China School of Medicine, Sichuan University, Sichuan University Affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, Chengdu, China.
Nuo XuDepartment of Oncology, West China School of Medicine, Sichuan University, Sichuan University Affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, Chengdu, China.
Wenyang WangDepartment of Oncology, West China School of Medicine, Sichuan University, Sichuan University Affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, Chengdu, China.
Shipai ZhuRadiotherapy Physics & Technology Center, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
An LiRadiotherapy Physics & Technology Center, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Shoupeng LiuDepartment of Oncology, Chengdu Fifth People's Hospital, China.
Jialu LaiRadiotherapy Physics & Technology Center, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xiaodong PengDepartment of Oncology, West China School of Medicine, Sichuan University, Sichuan University Affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, Chengdu, China.
Renming ZhongRadiotherapy Physics & Technology Center, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Magnetic resonance-guided linear accelerators (MR-Linacs) have recently been introduced for radiotherapy of brain metastases (BMs), including hypofractionated stereotactic radiotherapy (HSRT). However, optimal strategies for planning HSRT within MR-guided adaptive workflows remain to be established. This study aimed to evaluate the influence of field number and minimum monitor unit per segment (MU/segment) on plan quality, and robustness of dose calculations in MR-guided HSRT for patients with solitary medium-sized BMs. Methods: This retrospective study included 20 patients who underwent HSRT for solitary medium-sized BMs, receiving a prescription dose of 30 Gy in three fractions. Four intensity-modulated radiotherapy (IMRT) plans were systematically generated for each patient by varying the number of fields (9 Results: All four IMRT configurations provided clinically acceptable plans with similar target coverage and no significant differences in conformity, gradient, or homogeneity indices (all P>0.05). Although some dose parameters for normal brain tissue reached statistical significance (overall P<0.001), absolute differences were minor (≤1 cm Conclusions: The 15FL-IMRT configuration provided an optimal balance among plan quality, deliverability, and robustness of dose calculation, supporting its adoption as the preferred planning approach for MR-guided HSRT in patients with solitary medium-sized BMs.

Indexed as

brain metastases (BMs)hypofractionated stereotactic radiotherapy (HSRT)Magnetic resonance-guided linear accelerator (MR-Linac)plan qualityrobustness

Identifiers

PMID42433530
PMCPMC13350009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.